Ensysce Biosciences, Inc. (ENSC) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -829.11%.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -6,595,387.4 | 0.00 | 1,053.57 | 0.00 | - |
| 2018 | -158,096.9 | -38.27 | 1,075.65 | 0.00 | - |
| 2019 | -22,617.2 | 108.17 | -34,223.64 | 129,529.84 | - |
| 2020 | 3,515,272.4 | 26,364.54 | -30,984.03 | 50,763.52 | - |
| 2021 | -48.9 | 0.00 | -180.44 | 402.58 | - |
| 2022 | -1.0 | 0.02 | -6.54 | 9.63 | - |
| 2023 | -3.4 | 0.04 | -111.50 | 16.14 | - |
| 2024 | -1.8 | 0.70 | 3.83 | 2.73 | 2,039.30% |
| 2025 | 0.0 | 0.00 | 0.00 | 0.46 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.01 | $0.00 | $-31.19K | - |
| 2018 | $-0.22 | $0.00 | $-1.34M | - |
| 2019 | $0.24 | $1.76M | $365.95K | 20.7% |
| 2020 | $0.56 | $3.93M | $56.77K | 1.4% |
| 2021 | $-346.90 | $3.53M | $-29.08M | -823.7% |
| 2022 | $-139.44 | $2.52M | $-24.17M | -958.1% |
| 2023 | $-4.69 | $2.23M | $-10.61M | -475.7% |
| 2024 | $-4.57 | $5.21M | $-7.99M | -153.3% |
| 2025 | $-397,896.00 | $0.00 | $-10.18T | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.29 | $-0.29 – $-0.29 | $2.5M | $2.5M – $2.5M | 1 |
| 2027 | $-0.20 | $-0.20 – $-0.20 | $35.12M | $35.12M – $35.12M | 1 |
